News
The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.
Clinical Trials Arena on MSN19h
Alumis concludes enrolment in Phase III programme of plaque psoriasis therapyThe programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback